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Vemurafenib (Zelboraf™, Genentech, CA) is a highly effective oral chemotherapy agent for patients with 
metastatic melanoma who carry the BRAF V600E mutation.  Side effects of this protein kinase inhibitor 
(PKI) include arthralgia, rash, and fatigue which are reported in up to one-third of treated patients. Mild 
abnormalities in liver biochemistries were reported with vemurafenib use in 30% of subjects, 11% 
developed severe laboratory abnormalities and acute liver failure has been reported (Table 1). Herein, a 
case of severe vemurafenib induced granulomatous hepatitis leading to chronic cholestatis is reported 
along with a review of the hepatoxicity of other PKI’s.   
Case Report 
A 69 year old Caucasian man with metastatic melanoma began vemurafenib 240 mg twice daily that was 
titrated to 720 mg twice daily after two weeks. Six weeks after starting therapy, the patient was 
hospitalized with vomiting and abdominal pain with a serum alanine aminotransferase (ALT) 45 U/L, 
aspartate aminotransferase (AST) 36 U/L, alkaline phosphatase (ALP) 209 U/L and total bilirubin 1.3 
mg/dl.  Despite drug discontinuation, his liver enzymes peaked 7 days later with an ALT 170 U/L, AST 132 
U/L, ALP 663 U/L and bilirubin of 6.0 mg/dl. Serologies against hepatitis A, B, C, E , CMV, EBV, anti-
smooth muscle, ANA and AMA as well as  quantitative HCV RNA were negative. An abdominal CT scan 
revealed splenomegaly without biliary dilation. There was no eosinophilia and the INR remained normal 
throughout.  
Concomitant medications started greater than 6 months prior included atenolol, naproxen, and tadalafil. 
He denied alcohol use and reported no dietary or herbal supplement use. A liver biopsy 7 days after DILI 
onset revealed cholestatic injury with granulomas and eosinophils (Figure 1). The patient improved 
clinically but the ALP remained elevated at 302 IU/L with a normal bilirubin eight months after 
presentation. The causality score in the Drug Induced Liver Injury Network protocol was highly likely for 
vemurafenib hepatotoxicity.  The patient subsequently received dabrafenib 100 mg twice daily with 
good disease response but it was later discontinued after 12 months due to inflammatory arthritis and 
uveitis.  
Discussion 
Protein kinases are a family of regulatory enzymes that catalyze phosphorylation of specific intracellular 
protein residues leading to changes in protein function including cell proliferation. For this reason, the 
PKIs have become a major focus of cancer drug development. PKIs can target tyrosine and/or 
serine/threonine residues. Although tyrosine kinase inhibitor (TKI) use has expanded dramatically in the 
last five years, most of these agents have been associated with hepatotoxicity during clinical trials and 
several have been withdrawn from the market for severe hepatotoxicity (Table 1). Although 
vemurafenib is a serine-threonine kinase inhibitor, it appears to have many of the same hepatotoxic 
effects as TKIs (1,2). 
The mechanism of injury with vemurafenib hepatotoxicity is unknown.  Acholestatic or mixed pattern of 
liver injury was more common at presentation compared to a hepatocellular injury pattern (65% vs 35%) 
in 63 patients with vemurafenib hepatotoxicity (2).  Most patients presented within 2 months of drug 
initiation and the estimated reporting rate of vemurafenib hepatotoxicity was 5.13 (95% CI, 3.8-6.4) per 
1000-patient years’ exposure.  
Confidently identifying drug induced liver injury (DILI) in oncology patients receiving chemotherapy can 
be challenging. Malignant involvement of the liver, ischemic hepatopathy, cholestasis of sepsis, HBV 
reactivation, herpes hepatitis and non-chemotherapy associated DILI must all be considered. Therefore, 
many clinicians obtain a liver biopsy to help exclude competing causes of liver injury and confirm a 
diagnosis of DILI.  Vemurafenib-associated DILI can be treated by dose reduction or discontinuation. In 
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the aforementioned case series, 17 patients (27 %) were continued on vemurafenib at a decreased dose 
and 25 patients were rechallenged after discontinuation, with 20 being able to complete therapy (2).  
There is a potential for synergistic hepatotoxicity when PKI’s are used with other potentially hepatotoxic 
chemotherapeutic agents. In one study of 10 patients with metastatic melanoma who received both 
vemurafenib and ipilibumab, a CTLA4 inhibitor, 7 developed treatment-limiting DILI within five weeks 
with prominent auto-immune hepatitis like features (3).  Although the hepatotoxic effects of PKI’s are 
well documented, use of these agents will likely continue to increase due to their dramatic clinical 
benefit observed in individual patients with otherwise fatal malignancies.  Therefore, consulting 
physicians should become familiar with the hepatotoxicity profile of this rapidly expanding class of 
agents via use of electroniclectronic databases such as LiverTox  (http://livertox.nih.gov/).  
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Figure1 . Granulomatous hepatitis associated with Vemurafenib use.  A. Poorly formed granulomatous 
inflammation in a portal area. (H&E, 400x)  B. Lymphocytic infiltration of the bile ducts (arrow). (H&E, 
400x) C. Canalicular cholestasis (arrow) in zone 3. (H&E, 600x)  
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Table 1. Hepatotoxicity of approved protein kinase inhibitors.  
 
Drug Approved indication(s) %  AST/ALT elevation  
[% grade 3-4] 
Latency to liver 
injury onset 
Fatal hepatic failure 
reported 
Axitinib RCC 22 [<1] N/A No 
Bosutinib CML 20 [6-10] Median 30-33 days No 
Cabozantinib Medullary thyroid cancer 86 [3-6] N/A No 
Ceritinib Non-small cell lung cancer 27 [<1]  N/A No 
Crizotinib Non-small cell lung cancer 76 [17] <2 months Yes 
Dabrafenib Metastatic melanoma 25 [0.5]  
a
 N/A No 
Dasatinib CML, ALL 0-5 [0] N/A No 
Erlotinib Non-small cell lung cancer, 
pancreatic cancer 
35-45 [10-14]* <2-4 weeks Yes^ 
Gefitinib Non-small cell lung cancer 11-40 [2-5] N/A No 
Ibrutinib B cell malignancies None reported N/A No 
Idelalisib CLL 35-50 [14] <12 weeks Yes (Black box warning) 
Imatinib CML, ALL, hypereosinophlic 
syndrome, myelodysplasia, GIST 
6-12 [3-6] 12-77 days Yes 
Lapatinib HER-2-positive breast cancer 37-53 [2-6] Days to months Yes (Black Box warning) 
Lenvatinib Thyroid cancer, metastatic RCC [5] N/A Yes 
Nilotinib CML 72 [4] N/A No 
Nintedanib Non-small cell lung cancer 14 N/A No 
Palbociclib ER-pos HER2-neg breast cancer None reported N/A No 
Pazopanib RCC, soft tissue sarcoma 46-53 [7-12] <18 weeks Yes (Black box warning) 
Ponatinib CML, AML  56 [8] N/A Yes (Black box warning) 
Regorafenib Colorectal cancer 58-65 [5-6] N/A Yes (Black box warning) 
Ruxolitinib myelofibrosis 25 [<1] N/A No 
Sorafenib RCC, hepatocellular carcinoma, 
thyroid cancer 
21-59 [2-4] N/A No 
Sunitinib GIST, RCC, pancreatic 
neuroendocrine tumor 
56-78 [3-5] N/A Yes (Black box warning) 
Tofacitinib Rheumatoid arthritis None reported N/A No 
Trametinib Metastatic melanoma 60 [2] N/A No 
Vandetanib Medullary thyroid cancer 51 [2] N/A No 
Vemurafenib Melanoma with BRAF mutations 30 [11] 3 to 6 weeks No 
RCC, renal cell cancer; CML, chronic myeloid leukemia; ALP, alkaline phosphatase; ALL, acute lymphoblastic leukemia; GIST, gastrointestinal 
stromal tumor; ER-pos, estrogen receptor positive; HER2-pos, human epidermal growth factor receptor 2 positive  N/A= Not available 
A
 alkaline phosphatase elevations; *when used in combination with gemcitabine for pancreatic cancer (4% AST/ALT elevation with 
monotherapy); ^when used in Childs B cirrhosis 
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